시장 영업 전: 1.24

FibroGen Inc (FGEN)

FibroGen Inc 주식(FGEN)의 최신 뉴스

FibroGen Inc (FGEN)

FibroGen Inc 주식(FGEN)의 최신 뉴스

FibroGen (FGEN) Price Target Increased by 40.00% to 1.79 - MSN

Q2 2024 EPS Estimates for FibroGen, Inc. Raised by Analyst (NASDAQ:FGEN) - MarketBeat

Q1 2025 Earnings Forecast for FibroGen, Inc. Issued By William Blair (NASDAQ:FGEN) - Defense World

3 Penny Stocks to Watch Now - TipRanks.com - TipRanks

FibroGen (FGEN) Q2 Earnings and Revenues Top Estimates - Yahoo News UK

FibroGen (NASDAQ:FGEN) Share Price Passes Above 50-Day Moving Average of $1.70 - MarketBeat

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks ... - MSN

FibroGen First Quarter 2024 Earnings: Beats Expectations - Simply Wall St

FibroGen (NASDAQ:FGEN) Stock Price Crosses Above 50 Day Moving Average of $1.70 - Defense World

FibroGen First Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Traders Rush To Buy Biotech Following Q1 Earnings Beat - The Globe and Mail

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks ... - Investing.com UK

FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript - Insider Monkey

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet - Simply Wall St

FibroGen to Participate in Upcoming Investor Conferences - Yahoo Canada Finance

Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline - Investing.com India

Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline - Investing.com

FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and Strategic Advances - GuruFocus.com

Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks ... - Investing.com UK

FibroGen Reports First Quarter 2024 Financial Results - GlobeNewswire

FibroGen Reports First Quarter 2024 Financial Results

FibroGen Reports First Quarter 2024 Financial Results - Investing.com ZA - Investing.com South Africa

FibroGen Reports First Quarter 2024 Financial Results - 06.05.2024 - wallstreet:online

FibroGen (FGEN) Scheduled to Post Earnings on Monday - Defense World

Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates

FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo New Zealand News

FibroGen to Report First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results - Yahoo Finance

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies

Here's Why You Should Add Immunovant (IMVT) to Your Portfolio

Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug

Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study

FibroGen, Kind Pharma settle trade secrets theft dispute - FiercePharma

DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch

Intra-Cellular (ITCI) Up as Depression Drug Meets Study Goals

Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up

Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Eyenovia (EYEN) Down 18% on Disappointing Corporate Update

Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study

Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why

eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The - Benzinga

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FGEN과 유사한 종목